Technology promotes the decline of new drug research and development costs or will rewrite the market competition
September 18, 2014 Source: Bio Valley
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Over the past 200 years, the constant changes in technology have continually rewritten the development of the industry landscape. The current development of technologies such as Internet medical and gene sequencing may bring about certain changes in traditional pharmaceutical research and development, and thus change the competitive landscape of the pharmaceutical market.
First, the large-scale development of the gene sequencing industry has finally affected drug development. Recently, AstraZeneca announced that it will use the gene sequencing company Illumina technology and the company's new diagnostic agents to create the first diagnostic tool based on sequencer technology. Illumina's sequencing platform quickly sorts multiple genes faster and cheaper, and searches for all possible genetic variants.
With the development of gene sequencing technology, the cost and time required for gene sequencing have been greatly reduced. By analyzing the genes of clinical patients, it can help companies to better predict the acceptance and efficacy of new drugs in patients.
Second, the tide of Internet medical care has brought good news to R&D. Data service provider Comprehend Systems has recently received another $21 million in investment. Comprehend Systems provides cloud-based, cross-data-based, visual data analysis tools for clinical data visualization analysis.
For pharmaceutical companies, clinical trials are an essential part of the process and a key part of their approval. However, these data are currently stored in different places and are not integrated. Although it is convenient for different practitioners to evaluate the data, it does not help them to coordinate with each other. When Comprehend Systems integrates all of this information into a single platform, the company's management, medical operations, data management, and data monitoring equals all personnel involved in clinical trials to analyze, collaborate, and review data on the same platform. This will save time and cost for development.
It can be seen from the above two cases that new technologies are driving the speed of drug development and effectively reducing the cost of research and development. From this perspective, the future pharmaceutical market may bring some changes.
First, small and medium-sized pharmaceutical companies may take more active positions in the market. With the decline in research and development costs and the shortening of the R&D process, the funds required for the development of new drugs will decline to a certain extent, which is beneficial to companies with insufficient funds. When R&D investment is no longer so daunting, small and medium-sized pharmaceutical companies can successfully turn over and seize a few successful products, and occupy a place in the fierce competition in the pharmaceutical market.
Second, the research and development of new drugs will usher in a new climax. As the cost of research and development declines, not only small enterprises can get involved in the research and development of new drugs, but also large companies can more effectively allocate the original funds to further promote the development and listing of new drugs. .
Third, mergers and acquisitions will continue, but mergers between large companies may decrease. As the cost of research and development of new drugs declines, there will be more new entrants in the market, which means that there will be more M&A targets. Large companies will pay more attention to small companies with innovative capabilities, and through the acquisition of these small companies to acquire new products to promote their own development. The pressure of patent drug expiration is an important reason for large companies to acquire each other, but if there are new core patent products, these big companies may choose to stick to their own development.
With the development of this round of new technologies, the threshold for new drug research and development will definitely be further reduced in the future, which will have a positive impact on the market. Conversely, in the future, there will be more entrepreneurs influx into this market segment related to new drug research and development, and further strengthen the professionalism of mobile medical care.
Puyang Linshi Medical Supplies Co., Ltd. , https://www.linshimedicals.com